New drug combo could slash Years-Long wait for kidney transplants
NCT ID NCT05017545
First seen Feb 28, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This study tests whether two drugs, carfilzomib and belatacept, can lower the immune sensitivity of kidney transplant candidates who are highly sensitized—meaning their bodies reject most donor kidneys. The goal is to make it easier and quicker to find a compatible donor. About 21 participants with end-stage kidney disease will receive the drugs and be monitored for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Transplant Center, Duke University Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.